Novo’s hunt for genetic med tech drove $600m NanoVation pact

The partnership will combine NanoVation’s long-circulating lipid nanoparticle (lcLNP) technology for RNA delivery to cells outside of the liver with Novo’s clinical translation and R&D knowledge in cardiometabolic and rare diseases. In addition to the exclusive license for two lead programs for Novo, the deal includes up to five more targets in rare and cardiometabolic diseases explored.

According to NanoVation, its lcLNP platform aids functional nucleic acid delivery to extrahepatic cell types and preclinical studies have showcased an enhanced therapeutic index.

“Over the past several months, we participated in a highly collaborative process to develop the work plans for the leads programs and negotiate the partnership agreement,” a spokesperson for NanoVation told BioXconomy.

“Novo Nordisk reached out to us because they were looking for novel technologies that could address some of the biggest delivery challenges in genetic medicines, with a focus on cardiometabolic and rare diseases.”  

The spokesperson explained how the two companies “share a vision of developing transformative therapies that push the boundaries of what is possible in genetic medicine.” Additionally, NanoVation’s IP portfolio and “capabilities around extrahepatic nucleic acid delivery” were of particular interest to Novo.

Under the terms of the deal, NanoVation will be responsible for development of technology and advancement of the firm’s LNP delivery systems. Meanwhile, Novo will provide its expertise in disease biology, preclinical, and clinical development.

“Ultimately, success hinges on our close collaboration, clear communication and adaptability as scientific and clinical data emerge. We have robust systems to ensure that happens between and among the scientific and management teams, and will maintain a flexible, data-driven approach so we can adapt quickly as scientific or clinical data emerges,” said the spokesperson.

R&D efforts will take place at NanoVation’s laboratories in Vancouver, Canada, as well as Novo’s R&D facilities.

“The dual-location strategy leverages each company’s […] facilities and expertise, and ensures the best possible resources are applied to each phase of the project,” they told us.

NanoVation will receive an undisclosed amount of research funding from Novo and is eligible to gain up to $600 million in upfront cash and milestone payments, dependent on future sales as part of the multi-year deal.